The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Open accessAbstract
BACKGROUND: Approximately 50% of melanomas harbor activating (V600) mutations in the serine-threonine protein kinase B-RAF (BRAF). The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced tumor regressions in patients with BRAF V600-mutant metastatic melanoma in a phase 1 trial and improved overall survival in a phase 3 trial. METHODS: We designed a multicenter phase 2 trial of vemurafenib in patients with previously treated BRAF V600-mutant metastatic melanoma to investigate the efficacy of vemurafenib with respect to overall response rate (percentage of treated patients with a tumor response), duration of response, and overall survival. The primary end point was the overall response rate as ascertained by the independent review committee; overall survival was a secondary end point. RESULTS: A total of 132 patients had a median follow-up of 12.9 months (range, 0.6 to 20.1). The confirmed overall response rate was 53% (95% confidence interval [CI], 44 to 62; 6% with a complete response and 47% with a partial response), the median duration of response was 6.7 months (95% CI, 5.6 to 8.6), and the median progression-free survival was 6.8 months (95% CI, 5.6 to 8.1). Primary progression was observed in only 14% of patients. Some patients had a response after receiving vemurafenib for more than 6 months. The median overall survival was 15.9 months (95% CI, 11.6 to 18.3). The most common adverse events were grade 1 or 2 arthralgia, rash, photosensitivity, fatigue, and alopecia. Cutaneous squamous-cell carcinomas (the majority, keratoacanthoma type) were diagnosed in 26% of patients. CONCLUSIONS: Vemurafenib induces clinical responses in more than half of patients with previously treated BRAF V600-mutant metastatic melanoma. In this study with a long follow-up, the median overall survival was approximately 16 months. (Funded by Hoffmann-La Roche; ClinicalTrials.gov number, NCT00949702.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, BRAF inhibitors led to a monotherapy response rate of >50% in BRAFV600E melanoma and ~30% in BRAFV600E NSCLC, but only ~5% in BRAFV600E colorectal cancer, likely due to the variable robustness of adaptive feedback networks in each tumor type (45–49).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [45]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationToxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationInhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citationMelanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Self-citationAtkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G. R., Margolin, K. A., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,043
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,003
Patient-centric trials for therapeutic development in precision oncology
Biankin, A. V., Piantadosi, S., & Hollingsworth, S. J. (2015) · Nature · doi:10.1038/nature15819 · Cited by 286
Ultraviolet Radiation Exposure and Its Impact on Skin Cancer Risk
Watson, M., Holman, D. M., & Maguire-Eisen, M. (2016) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2016.05.005 · Cited by 280
High-resolution interrogation of functional elements in the noncoding genome
Sanjana, N. E., Wright, J. B., Zheng, K., Shalem, O., Fontanillas, P., Joung, J., Cheng, C. S., Regev, A., & Zhang, F. (2016) · Science · doi:10.1126/science.aaf7613 · Cited by 290
Larkin, J., Vecchio, M. D., Ascierto, P. A., Krajsová, I., Schachter, J., Neyns, B., Espinosa, E., Garbe, C., Chiarion‐Sileni, V., Gogas, H. J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70051-8 · Cited by 282
Codon-specific translation reprogramming promotes resistance to targeted therapy
Rapino, F., Delaunay, S., Rambow, F., Zhou, Z., Tharun, L., De Tullio, P., Sin, O., Shostak, K., Schmitz, S., Piepers, J., et al. (2018) · Nature · doi:10.1038/s41586-018-0243-7 · Cited by 271
Selection and adaptation during metastatic cancer progression
Klein, C. A. (2013) · Nature · doi:10.1038/nature12628 · Cited by 275
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Knight, D. A., Ngiow, S. F., Li, M., Parmenter, T. J., Mok, S., Cass, A. A., Haynes, N. M., Kinross, K. M., Yagita∥, H., Koya, R. C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66236 · Cited by 274
Self-citationRetractedEpithelioid GBMs Show a High Percentage of BRAF V600E Mutation
Kleinschmidt-DeMasters, B. K., Aisner, D. L., Birks, D. K., & Foreman, N. K. (2013) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31827f9c5e · Cited by 261
Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
Cooper, Z. A., Juneja, V. R., Sage, P. T., Frederick, D. T., Piris, A., Mitra, D., Lo, J. A., Hodi, F. S., Freeman, G. J., Bosenberg, M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0215 · Cited by 264
Self-citationResistant mechanisms to BRAF inhibitors in melanoma
Manzano, J. L., Layos, L., Bugés, C., Gil, M. D. L. L., Vilà, L., Martinez‐Balibrea, E., & Martínez‐Cardús, A. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.06.07 · Cited by 271
Systemic treatments for metastatic cutaneous melanoma
Pasquali, S., Hadjinicolaou, A. V., Chiarion‐Sileni, V., Rossi, C. R., & D, S. M. M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011123.pub2 · Cited by 258
McArthur, G. A., Maio, M., Arance, A. M., Nathan, P., Blank, C. U., Avril, M.-F., Garbe, C., Hauschild, A., Schadendorf, D., Hamid, O., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw641 · Cited by 253
Self-citationIhle, M. A., Fassunke, J., König, K., Grünewald, I., Schlaak, M. S., Kreuzberg, N., Tietze, L., Schildhaus, H., Büttner, R., & Merkelbach‐Bruse, S. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-13 · Cited by 251
Targeting Oncogenic BRAF: Past, Present, and Future
Zaman, A., Wu, W., & Bivona, T. G. (2019) · Cancers · doi:10.3390/cancers11081197 · Cited by 252
Orphan nuclear receptor TR3 acts in autophagic cell death via mitochondrial signaling pathway
Wang, W.-J., Wang, Y., Chen, H., Xing, Y.-Z., Li, F.-W., Zhang, Q., Zhou, B., Zhang, H., Zhang, J., Bian, X., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1406 · Cited by 253
Sanmamed, M. F., Landazuri, S. F., Rodríguez, C., Zárate, R., Lozano, M. D., Zubiri, L., Perez‐Gracia, J. L., Martín‐Algarra, S., & González, Á. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2014.230235 · Cited by 249
Molecular Markers and Targets in Melanoma
Teixidó, C., Castillo, P., Martínez-Vila, C., Arance, A. M., & Alós, L. (2021) · Cells · doi:10.3390/cells10092320 · Cited by 262
Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment
Callahan, M. K., Rampal, R. K., Harding, J. J., Klimek, V. M., Chung, Y. R., Merghoub, T., Wolchok, J. D., Solit, D. B., Rosen, N. X., Abdel-Wahab, O. I., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208958 · Cited by 243
Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
Heinzerling, L., Eigentler, T., Fluck, M., Hassel, J. C., Heller-Schenck, D., Leipe, J., Pauschinger, M., Vogel, A., Zimmer, L., & Gutzmer, R. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000491 · Cited by 242
BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy
Koya, R. C., Mok, S., Otte, N. J., Blacketor, K. J., Comin-Anduix, B., Tumeh, P. C., Minasyan, A., Graham, N. A., Graeber, T. G., Chodon, T., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2837 · Cited by 234
Self-citationYu, H., Steeghs, N., Nijenhuis, C. M., Schellens, J. H. M., Beijnen, J. H., & Huitema, A. D. R. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0137-2 · Cited by 233
Targeting the BRAF V600E Mutation in Multiple Myeloma
Andrulis, M., Lehners, N., Capper, D., Penzel, R., Heining, C., Hüellein, J., Zenz, T., von Deimling, A., Schirmacher, P., Ho, A. D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0014 · Cited by 236
Girotti, M. R., Gremel, G., Lee, R. J., Galvani, E., Rothwell, D. G., Virós, A., Mandal, A. K., Lim, K. H. J., Saturno, G., Furney, S. J., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1336 · Cited by 235
Self-citationGarbe, C., Peris, K., Hauschild, A., Saïag, P., Middleton, M. R., Spatz, A., Grob, J., Malvehy, J., Newton‐Bishop, J., Stratigos, A., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.06.013 · Cited by 233
Comprehensive Analysis of Cuproptosis-Related Genes in Immune Infiltration and Prognosis in Melanoma
Lv, H., Liu, X., Zeng, X., Liu, Y., Zhang, C.-J., Zhang, Q., & Xu, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.930041 · Cited by 233
Metastatic Melanoma – A Review of Current and Future Treatment Options
Maverakis, E., Cornelius, L. A., Bowen, G., Phan, T., Patel, F., Fitzmaurice, S., He, Y., Burrall, B. A., Duong, C., Kloxin, A. M., et al. (2014) · Acta Dermato Venereologica · doi:10.2340/00015555-2035 · Cited by 227
Ackerman, A., Klein, O., McDermott, D. F., Wang, W., Ibrahim, N., Lawrence, D. P., Gunturi, A., Flaherty, K. T., Hodi, F. S., Kefford, R. F., et al. (2014) · Cancer · doi:10.1002/cncr.28620 · Cited by 223
Self-citationCancer Neoantigens and Applications for Immunotherapy
Desrichard, A., Snyder, A., & Chan, T. A.-T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3175 · Cited by 219
Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma
Lacouture, M. E., Duvic, M. A., Hauschild, A., Prieto, V. G., Robert, C., Schadendorf, D., Kim, C. C., McCormack, C. J., Myskowski, P. L., Spleiss, O., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0333 · Cited by 217
Self-citationJohnson, D. B., Flaherty, K. T., Weber, J. S., Infante, J. R., Kim, K. B., Kefford, R. F., Hamid, O., Schuchter, L. M., Cebon, J. S., Sharfman, W. H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3535 · Cited by 219
Self-citationEuropean consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019
Garbe, C., Amaral, T. M. S., Peris, K., Hauschild, A., Arenberger, P., Bastholt, L., Bataille, V. A., del Mármol, V., Dréno, B., Fargnoli, M. C., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.11.015 · Cited by 218
Kim, G., McKee, A. E., Ning, Y. M., Hazarika, M., Theoret, M. R., Johnson, J. R., Xu, Q. C., Tang, S., Sridhara, R., Jiang, X., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0776 · Cited by 219
Hou, S., Zhao, L., Shen, Q., Yu, J., Ng, C., Kong, X., Wu, D., Song, M., Shi, X., Xu, X., et al. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201208452 · Cited by 212
Self-citationGirotti, M. R., Lopes, F., Preece, N., Niculescu-Duvaz, D., Zambon, A., Davies, L., Whittaker, S., Saturno, G., Viros, A., Pedersen, M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.006 · Cited by 212
Drug resistance to targeted therapies: Déjà vu all over again
Groenendijk, F. H., & Bernards, R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.004 · Cited by 222
Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges
Zhao, Y., Deng, J. M., Rao, S., Guo, S., Shen, J., Du, F., Wu, X., Chen, Y., Li, M., Chen, M., et al. (2022) · Cancers · doi:10.3390/cancers14174160 · Cited by 215
Self-citationCutaneous toxicities of RAF inhibitors
Anforth, R. M., Fernández‐Peñas, P., & Long, G. V. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70413-8 · Cited by 204
Gopal, Y. N. V., Rizos, H., Chen, G., Deng, W., Frederick, D. T., Cooper, Z. A., Scolyer, R. A., Pupo, G. M., Komurov, K., Sehgal, V., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1392 · Cited by 203
Lovly, C. M., Dahlman, K. B., Fohn, L. E., Su, Z., Dias-Santagata, D. C., Hicks, D. J., Hucks, D., Berry, E., Terry, C. R., Duke, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035309 · Cited by 203
Self-citationLian, B., Si, L., Cui, C., Chi, Z., Sheng, X., Mao, L., Li, S., Kong, Y., Tang, B., & Guo, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0739 · Cited by 202
Prevalence and detection of low-allele-fraction variants in clinical cancer samples
Shin, H., Choi, Y., Yun, J. W., Kim, N. K. D., Kim, S., Jeon, H. J., Nam, J., Lee, C., Ryu, D., Kim, S. C., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01470-y · Cited by 204
Self-citationDurable benefit and the potential for long-term survival with immunotherapy in advanced melanoma
McDermott, D. F., Lebbé, C., Hodi, F. S., Maio, M., Weber, J. S., Wolchok, J. D., Thompson, J. A., & Balch, C. M. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.06.012 · Cited by 205
Self-citationYang, J., & Hu, L. (2018) · Medicinal Research Reviews · doi:10.1002/med.21530 · Cited by 201
Management of conjunctival malignant melanoma: a review and update
Wong, J. R., Nanji, A., Galor, A., & Karp, C. L. (2014) · Expert Review of Ophthalmology · doi:10.1586/17469899.2014.921119 · Cited by 198
Nathanson, K. L., Martin, A., Wubbenhorst, B. S., Greshock, J. D., Letrero, R., D'Andrea, K. P., O'Day, S. J., Infante, J. R., Falchook, G. S., Arkenau, H., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0827 · Cited by 200
Self-citationBRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions
Proietti, I., Skroza, N., Michelini, S., Mambrin, A., Balduzzi, V., Bernardini, N., Marchesiello, A., Tolino, E., Volpe, S., Maddalena, P., et al. (2020) · Cancers · doi:10.3390/cancers12071823 · Cited by 192
Melanoma: What do all the mutations mean?
Davis, E. J., Johnson, D. B., Sosman, J. A., & Chandra, S. (2018) · Cancer · doi:10.1002/cncr.31345 · Cited by 197
Self-citationHamid, O., Puzanov, I. J., Dummer, R., Schachter, J., DAUD, A. I., Schadendorf, D., Blank, C. U., Cranmer, L. D., Robert, C., Pavlick, A. C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.022 · Cited by 190
Self-citationTargeting the ERK Signaling Pathway in Melanoma
Savoia, P., Fava, P., Casoni, F., & Cremona, O. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061483 · Cited by 195
Villanueva, J., Infante, J. R., Krepler, C., Reyes-Uribe, P. I., Samanta, M., Chen, H., Li, B., Swoboda, R., Wilson, M. A., Vultur, A., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.023 · Cited by 200
Self-citationTyrosine Kinase Inhibitors: Views of Selectivity, Sensitivity, and Clinical Performance
Levitzki, A. (2012) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140341 · Cited by 190
MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy
Nawrocki, S. T., Griffin, P. R., Kelly, K. R., & Carew, J. S. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.707192 · Cited by 188
Wilson, M. A., & Schuchter, L. M. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-22539-5_8 · Cited by 191
Self-citationResistance to BRAF inhibitors induces glutamine dependency in melanoma cells
Baenke, F., Chaneton, B., Smith, M., van den Broek, N. J. F., Hogan, K., Tang, H., Virós, A., Martin, M. J., Galbraith, L. C. A., Girotti, M. R., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.08.003 · Cited by 191
Robinson, G. W., Orr, B. A., & Gajjar, A. J. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-258 · Cited by 185
Melanoma treatment: from conventional to nanotechnology
Mishra, H., Mishra, P. K., Ekielski, A., Jaggi, M., Iqbal, Z., & Talegaonkar, S. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2726-1 · Cited by 189
Which drug, and when, for patients with BRAF-mutant melanoma?
Jang, S., & Atkins, M. B. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70539-9 · Cited by 182
Corazao-Rozas, P., Guerreschi, P., Jendoubi, M., André, F., Jonneaux, A., Scalbert, C., Garçon, G., Malet‐Martino, M., Balayssac, S., Rocchi, S., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1420 · Cited by 188
Mittapalli, R. K., Vaidhyanathan, S., Dudek, A. Z., & Elmquist, W. F. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.201475 · Cited by 182
Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study
Chu, E. Y., Wanat, K. A., Miller, C. J., Amaravadi, R. K., Fecher, L. A., Brose, M. S., McGettigan, S., Giles, L. R., Schuchter, L. M., Seykora, J. T., et al. (2012) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2012.04.008 · Cited by 182
Self-citationCutaneous adverse effects of targeted therapies
Macdonald, J. B., Macdonald, B., Golitz, L. E., LoRusso, P. M., & Sekulić, A. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.07.033 · Cited by 178
The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma
Kim, A., & Cohen, M. S. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1201057 · Cited by 178
Current Advances in the Treatment of BRAF-Mutant Melanoma
Patel, H. M., Yacoub, N., Mishra, R., White, A., Yuan, L., Alanazi, S., & Garrett, J. T. (2020) · Cancers · doi:10.3390/cancers12020482 · Cited by 184
Pencheva, N., Buss, C. G., Posada, J., Merghoub, T., & Tavazoie, S. F. (2014) · Cell · doi:10.1016/j.cell.2014.01.038 · Cited by 175
WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors
Anastas, J. N., Kulikauskas, R. M., Tamir, T. Y., Rizos, H., Long, G. V., von Euw, E. M., Yang, P., Chen, H., Haydu, L. E., Toroni, R. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70156 · Cited by 184
A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition
Shi, H., Hong, A., Kong, X., Koya, R. C., Song, C., Moriceau, G., Hugo, W., Yu, C. C., Ng, C., Chodon, T., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0279 · Cited by 178
Self-citationSurvival of patients with advanced metastatic melanoma: The impact of novel therapies
Ugurel, S., Röhmel, J., Ascierto, P. A., Flaherty, K. T., Grob, J., Hauschild, A., Larkin, J., Long, G. V., Lorigan, P. C., McArthur, G. A., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.09.013 · Cited by 179
Self-citationImmunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions
Mao, L., Qi, Z., Zhang, L., Guo, J., & Si, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.680407 · Cited by 181
Melanoma: Molecular Pathogenesis and Therapeutic Management.
Liu, Y., & Sheikh, M. S. (2014) · PubMed · Cited by 173
Miller, J. A., Bennett, E., Xiao, R., Kotecha, R. R., Chao, S. T., Vogelbaum, M. A., Barnett, G. H., Angelov, L., Murphy, E. S., Yu, J. S., et al. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.08.039 · Cited by 169
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall
Leonetti, A., Facchinetti, F., Rossi, G., Minari, R., Conti, A., Friboulet, L., Tiseo, M., & Planchard, D. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.006 · Cited by 179
The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
Watson, I. R., Li, L., Cabeceiras, P. K., Mahdavi, M., Gutschner, T., Genovese, G., Wang, G., Fang, Z., Tepper, J. M., Stemke‐Hale, K., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1232-t · Cited by 173
Robert, C., Dummer, R., Gutzmer, R., Lorigan, P. C., Kim, K. B., Nyakas, M., Arance, A. M., Liszkay, G., Schadendorf, D., Cantarini, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70237-7 · Cited by 170
Self-citationWargo, J. A., Reuben, A., Cooper, Z. A., Oh, K. S., & Sullivan, R. J. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.007 · Cited by 172
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma
Lim, S. Y., Menzies, A. M., & Rizos, H. (2017) · Cancer · doi:10.1002/cncr.30435 · Cited by 169
Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth
Schöckel, L., Glasauer, A., Basit, F., Bitschar, K., Truong, H., Erdmann, G., Algire, C., Hägebarth, A., Willems, P. H., Kopitz, C., et al. (2015) · Cancer & Metabolism · doi:10.1186/s40170-015-0138-0 · Cited by 161
Carlos, G., Anforth, R. M., Clements, A., Menzies, A. M., Carlino, M. S., Chou, S., & Fernández‐Peñas, P. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.1745 · Cited by 163
Detection of BRAF p.V600E Mutations in Melanomas
Colomba, É., Hélias‐Rodzewicz, Z., von Deimling, A., Marin, C., Terrones, N., Pechaud, D., Surel, S., Côté, J.-F., Peschaud, F., Capper, D., et al. (2012) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2012.09.001 · Cited by 160
Acquired resistance to EGFR‐targeted therapies in colorectal cancer
Emburgh, B. O. V., Bianchi, A. S., Nicolantonio, F. D., Siena, S., & Bardelli, A. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.003 · Cited by 162
Somatic driver mutations in melanoma
Reddy, B. Y., Miller, D. M., & Tsao, H. (2017) · Cancer · doi:10.1002/cncr.30593 · Cited by 173
Dabrafenib and its potential for the treatment of metastatic melanoma
Murali, R., Menzies, A. M., & Long, G. V. (2012) · Drug Design Development and Therapy · doi:10.2147/dddt.s38998 · Cited by 165
PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
Luke, J. J., & Ott, P. A. (2015) · Oncotarget · doi:10.18632/oncotarget.2980 · Cited by 159
Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms
Liu, S., & Kurzrock, R. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.05.003 · Cited by 166
Meyer, U. A., Zanger, U. M., & Schwab, M. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100502 · Cited by 157
Coit, D. G., Andtbacka, R. H. I., Anker, C. J., Bichakjian, C. K., Carson, W. E., DAUD, A. I., DiMaio, D. J., Fleming, M. D., Guild, V., Halpern, A. C., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0055 · Cited by 160
MAP kinase signaling and inhibition in melanoma
Sullivan, R. J., & Flaherty, K. T. (2012) · Oncogene · doi:10.1038/onc.2012.345 · Cited by 162
Self-citationSynthetic lethality-mediated precision oncology via the tumor transcriptome
Lee, J. S., Nair, N. U., Dinstag, G., Chapman, L. M., Chung, Y., Wang, K., Sinha, S., Cha, H., Kim, D., Schperberg, A. V., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.030 · Cited by 158
Mutant-selective degradation by BRAF-targeting PROTACs
Alabi, S., Jaime-Figueroa, S., Yao, Z., Gao, Y., Hines, J., Samarasinghe, K. T. G., Vogt, L., Rosen, N., & Crews, C. M. (2021) · Nature Communications · doi:10.1038/s41467-021-21159-7 · Cited by 152
Harnessing the Power of the Immune System to Target Cancer
Lizee, G. A., Overwijk, W. W., Radvanyi, L. G., Gao, J., Sharma, P., & Hwu, P. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-112311-083918 · Cited by 154
Zhu, A. X., Borger, D. R., Kim, Y., Cosgrove, D. C., Ejaz, A. M., Alexandrescu, S. T., Groeschl, R. T., Deshpande, V., Lindberg, J. M., Ferrone, C. R., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3828-x · Cited by 150
Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations
Kinno, T., Tsuta, K., Shiraishi, K., Mizukami, T., Suzuki, M., Yoshida, A., Suzuki, K., Asamura, H., Furuta, K., Kohno, T., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt495 · Cited by 148
The Conundrum of Genetic “Drivers” in Benign Conditions
Kato, S., Lippman, S. M., Flaherty, K. T., & Kurzrock, R. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw036 · Cited by 149
Self-citationBRAF–MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas
Brastianos, P. K., Twohy, E., Geyer, S., Gerstner, E. R., Kaufmann, T. J., Tabrizi, S., Kabat, B., Thierauf, J., Ruff, M. W., Bota, D. A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2213329 · Cited by 146
Targeting PI3 kinase in cancer
Bauer, T. M., Patel, M. R., & Infante, J. R. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.09.006 · Cited by 153
Beck, D., Niessner, H., Smalley, K. S. M., Flaherty, K. T., Paraiso, K. H. T., Busch, C., Sinnberg, T. W., Vasseur, S., Iovanna, J., Drießen, S., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2003057 · Cited by 153
Self-citationMolecular Pathways and Mechanisms of BRAF in Cancer Therapy
Poulikakos, P. I., Sullivan, R. J., & Yaeger, R. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2138 · Cited by 145
Wimmers, F., Schreibelt, G., Sköld, A. E., Figdor, C. G., & de Vries, I. J. M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00165 · Cited by 149
Ramsdale, R., Jorissen, R. N., Li, F. Z., Al-Obaidi, S., Ward, T., Sheppard, K. E., Bukczynska, P. E., Young, R. J., Boyle, S. E., Shackleton, M., et al. (2015) · Science Signaling · doi:10.1126/scisignal.aab1111 · Cited by 143
Self-citationLamberti, G., Andrini, E., Sisi, M., Rizzo, A., Parisi, C., Federico, A. D., Gelsomino, F., & Ardizzoni, A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103119 · Cited by 147
Niessner, H., Forschner, A., Klumpp, B. D., Honegger, J. B., Witte, M. B., Bornemann, A., Dummer, R., ADAM, A., Bauer, J. M., Tabatabai, G., et al. (2012) · Cancer Medicine · doi:10.1002/cam4.50 · Cited by 143
Self-citation
Metadata
- Authors
- Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., Hersey, P., Kefford, R., Lawrence, D., Puzanov, I., Lewis, K. D., Amaravadi, R. K., Chmielowski, B., Lawrence, H. J., Shyr, Y., Ye, F., Li, J., Nolop, K. B., Lee, R. J., Joe, A. K., & Ribas, A.
- Affiliations
- Vanderbilt University (US)
- The University of Texas MD Anderson Cancer Center (US)
- Abramson Cancer Center (US)
- University of Colorado Denver (US)
- New York University (US)
- Moffitt Cancer Center (US)
- Peter MacCallum Cancer Centre (AU)
- University of Pittsburgh (US)
- Massachusetts General Hospital (US)
- University of Newcastle Australia (AU)
- Melanoma Institute Australia (AU)
- Vanderbilt-Ingram Cancer Center (US)
- University of California, Los Angeles (US)
- Vanderbilt University Medical Center (US)
- Plexxikon (United States) (US)
- ORCID
- Sosman, Jeffrey A.
- Kim, Kevin B.
- Schuchter, Lynn
- Gonzalez, Rene
- Pavlick, Anna C.
- Weber, Jeffrey S.
- McArthur, Grant A.
- Hutson, Thomas E.
- Moschos, Stergios J.
- Flaherty, Keith T.
- Hersey, Peter
- Kefford, Richard
- Lawrence, Donald
- Puzanov, Igor
- Lewis, Karl D.
- Amaravadi, Ravi K.
- Chmielowski, Bartosz
- Shyr, Yu
- Ye, Fei
- Li, Jiang
- Lee, Richard J.
- Ribas, Antoni
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-02-23
- Volume
- 366
- Issue
- 8
- Pages
- 707-714
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3724515
- OpenAlex
- W2168143310
- Cited by
- 2,156
- References
- 36
- Citations by year
- 2026: 19 · 2025: 29 · 2024: 56 · 2023: 85 · 2022: 113 · 2021: 88 · 2020: 110 · 2019: 109 · 2018: 132 · 2017: 171 · 2016: 198 · 2015: 258 · 2014: 318 · 2013: 306 · 2012: 160
- FWCI
- 133.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Figshare (submittedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- National Cancer Institute (K24CA097588, P30CA076292)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- vemurafenib, BRAF V600 mutation, metastatic melanoma, BRAF inhibitors, overall survival, overall response rate, duration of response, progression-free survival, cutaneous squamous cell carcinoma, keratoacanthoma, adverse events
- MeSH terms
- Vemurafenib, Adult, Aged, Female, Humans, Indoles, Male, Melanoma, Middle Aged, Mutation, Neoplasm Metastasis, Sulfonamides, Treatment Outcome, Disease Progression, Proto-Oncogene Proteins B-raf, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
